# Kisspeptin-10 Clinical Dosing Guidelines

## Overview
Kisspeptin-10 is a 10 amino acid peptide that acts as a potent stimulator of gonadotropin-releasing hormone (GnRH) secretion. It regulates the hypothalamic-pituitary-gonadal axis and has shown therapeutic potential for reproductive disorders and sexual function.

## Clinical Research Summary
Based on extensive human clinical trials, kisspeptin-10 has been studied for:
- Reproductive hormone regulation
- Treatment of hypogonadotropic hypogonadism  
- Enhancement of sexual arousal and function
- Ovulation induction and fertility treatment
- Assessment of GnRH neuronal function

## Standard Concentrations

### Reconstitution Options
- **Option 1**: 0.2 mg/ml (dilute 1 mg in 5 ml bacteriostatic water)
- **Option 2**: 0.1 mg/ml (dilute 1 mg in 10 ml bacteriostatic water)
- **Option 3**: 0.5 mg/ml (dilute 5 mg in 10 ml bacteriostatic water)

### Storage
- **Lyophilized**: Store at -4°F, stable for 24+ months
- **Reconstituted**: Store at 39°F, use within 28 days
- **Room Temperature**: Stable for 3 weeks unreconstituted

## Clinical Dosing Protocols

### Subcutaneous Administration (Primary Route)

#### Standard Research Protocol:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.1-0.2 mg per injection
- **Volume**: 0.5-1.0 ml
- **Frequency**: 2-3 times weekly
- **Injection Sites**: Abdomen, thigh, upper arm (rotate sites)

#### Low-Dose Protocol:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.07 mg (154 lb adult at 0.45 mcg/lb)
- **Volume**: 0.7 ml
- **Frequency**: Daily or every other day

#### High-Response Protocol:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.2-0.3 mg per injection
- **Volume**: 0.4-0.6 ml
- **Frequency**: 2 times weekly

### Reproductive Medicine Applications

#### Male Hypogonadism:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.1-0.15 mg per injection
- **Volume**: 0.5-0.75 ml
- **Frequency**: 3 times weekly
- **Duration**: 4-12 weeks with monitoring

#### Female Fertility Support:
- **Concentration**: 0.2 mg/ml
- **Dose**: 0.05-0.1 mg per injection
- **Volume**: 0.25-0.5 ml
- **Timing**: Cycle-specific administration
- **Monitoring**: Required with ultrasound and hormones

### Advanced Protocols

#### Pulse Therapy Simulation:
- **Concentration**: 0.1 mg/ml
- **Dose**: 0.05 mg per injection
- **Volume**: 0.5 ml
- **Frequency**: Every 2-3 hours during treatment period
- **Duration**: 8-12 hours treatment windows

## Dose Calculations by Body Weight

### Standard Dosing (0.45 mcg/lb - Optimal Response)
| Body Weight | Dose (mg) | Volume (0.2 mg/ml) | Volume (0.1 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.05 mg | 0.25 ml | 0.5 ml |
| 132 lbs | 0.06 mg | 0.30 ml | 0.6 ml |
| 154 lbs | 0.07 mg | 0.35 ml | 0.7 ml |
| 176 lbs | 0.08 mg | 0.40 ml | 0.8 ml |
| 198 lbs | 0.09 mg | 0.45 ml | 0.9 ml |
| 220 lbs | 0.10 mg | 0.50 ml | 1.0 ml |

### Conservative Dosing (0.225 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.2 mg/ml) | Volume (0.1 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.025 mg | 0.125 ml | 0.25 ml |
| 154 lbs | 0.035 mg | 0.175 ml | 0.35 ml |
| 198 lbs | 0.045 mg | 0.225 ml | 0.45 ml |

### High-Dose Protocol (0.9 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.2 mg/ml) | Volume (0.5 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.10 mg | 0.50 ml | 0.20 ml |
| 154 lbs | 0.14 mg | 0.70 ml | 0.28 ml |
| 198 lbs | 0.18 mg | 0.90 ml | 0.36 ml |
| 220 lbs | 0.20 mg | 1.00 ml | 0.40 ml |

## Administration Guidelines

### Injection Technique:
1. Use 27-30 gauge, 0.5-1 inch needle
2. Clean injection site with alcohol
3. Pinch skin and inject at 45-90 degree angle
4. Inject slowly over 10-15 seconds
5. Withdraw needle and apply pressure if needed

### Timing Considerations:
- **Best Results**: Empty stomach (2-3 hours post-meal)
- **Avoid**: Immediately before or after meals
- **Consistency**: Same time of day when possible
- **Cycle Timing**: Follow specific protocols for fertility applications

## Safety Parameters

### Baseline Testing:
- LH, FSH, testosterone/estradiol levels
- Liver function tests
- Cardiovascular assessment
- Pregnancy test (females of reproductive age)

### Monitoring During Treatment:
- Hormone levels at 2-4 week intervals
- Blood pressure and heart rate
- Sexual function assessment
- Side effect evaluation

### Contraindications:
- Pregnancy (unless specifically indicated)
- Active hormone-sensitive malignancies
- Uncontrolled cardiovascular disease
- Known hypersensitivity to kisspeptin

### Adverse Effects:
- Generally well-tolerated in clinical trials
- Minimal side effects reported
- No significant safety concerns at recommended doses
- Potential for desensitization with chronic high-dose use

## Special Considerations

### Desensitization Prevention:
- Use lowest effective dose
- Consider cycling protocols (on/off periods)
- Monitor hormone response regularly
- Adjust dosing based on individual response

### Gender-Specific Considerations:
- **Males**: Focus on testosterone and LH response
- **Females**: Cycle timing crucial for fertility applications
- **Nutritional Status**: Fasting vs fed state affects response

### Drug Interactions:
- Minimal known interactions
- Monitor when used with other reproductive hormones
- Consider timing with GnRH agonists/antagonists

## Clinical Endpoints

### Treatment Success Indicators:
- Improved LH and FSH levels
- Normalized testosterone/estradiol
- Enhanced sexual function scores
- Successful ovulation (fertility applications)
- Improved quality of life measures

### Duration of Treatment:
- **Short-term**: 4-8 weeks for initial response
- **Medium-term**: 12-24 weeks for sustained effects
- **Long-term**: Individual assessment required
- **Maintenance**: Lower dose protocols for sustained benefit